# Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

> **NCT00513786** · PHASE2 · COMPLETED · sponsor: **David O'Malley** · enrollment: 38 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00513786
- **Lead sponsor:** David O'Malley
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-01
- **Primary completion:** 2017-01-03
- **Final completion:** 2017-01-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513786, "Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00513786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*